GCTK (GlucoTrack) YoY EBITDA Growth: 92.11% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GCTK GlucoTrack Inc GCTK
19 GF Score
Price $2.30
! 2 Warning Signs
View Full Analysis

What is GlucoTrack YoY EBITDA Growth?

GlucoTrack GCTK 19 YoY EBITDA Growth is 92.11% as of Jun. 2026. GuruFocus rates GCTK with a GF Score™ of 19/100. The stock has 2 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. GlucoTrack's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 92.11%.

GlucoTrack's EBITDA per Share for the three months ended in Jun. 2026 was $-11.36.

GlucoTrack YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for GlucoTrack's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlucoTrack YoY EBITDA Growth Chart

GlucoTrack Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -48.29 -9.45 -19.68 -95.08 99.22

GlucoTrack Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 99.02 99.33 99.71 93.47 92.11
GCTK
19GF Score
GlucoTrack Inc GCTK
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GlucoTrack YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

GlucoTrack's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-465.847--59908.956)/ | -59908.956 |
=99.22 %

GlucoTrack's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(-11.358--143.932)/ | -143.932 |
=92.11 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 92.11% mean?
GlucoTrack (GCTK) has a YoY EBITDA Growth of 92.11% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for GlucoTrack and its competitors.
Is GlucoTrack's YoY EBITDA Growth too high?
GlucoTrack's current YoY EBITDA Growth is 92.11%. Overall, GlucoTrack has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does GlucoTrack's YoY EBITDA Growth compare to TNON and RMSL?
GlucoTrack's YoY EBITDA Growth of 92.11% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Devices & Instruments company?
A good YoY EBITDA Growth depends on the Medical Devices & Instruments industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for GlucoTrack and its competitors. GlucoTrack's current YoY EBITDA Growth is 92.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlucoTrack stock overvalued right now?
GlucoTrack (GCTK) has a current YoY EBITDA Growth of 92.11%. The current YoY EBITDA Growth is 92.11%. GlucoTrack's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For GlucoTrack (GCTK), the current YoY EBITDA Growth is 92.11% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GlucoTrack Business Description

Address 301 Route 17 North, Suite 800, Rutherford, NJ, USA, 07070
GlucoTrack Inc is a medical device company focused on the development of an implantable continuous blood glucose monitor (CBGM) for patients with Type 1 and Type 2 diabetes. The company is developing its Glucotrack CBGM system to provide continuous glucose monitoring using implantable sensor technology and is advancing the product through clinical studies and regulatory processes.
19GF Score

Get the complete analysis for GCTK

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.30
Price